Hal Barron, Endpoints UKBIO19

GSK, Vir's hopes for a Covid-19 an­ti­body fall flat in NIH 'mas­ter pro­to­col' with no ben­e­fit in hos­pi­tal­ized pa­tients

Glax­o­SmithK­line and Vir Biotech­nol­o­gy were hope­ful that one of their part­nered an­ti­bod­ies would carve out a win af­ter get­ting the in­vite to a ma­jor NIH study in hos­pi­tal­ized Covid-19 pa­tients. But just like Eli Lil­ly, the pair’s drug couldn’t hit the mark, and now they’ll be left to take a hard look at the game plan.

The NIH has shut down en­roll­ment for GSK and Vir’s an­ti­body VIR-7831 in its late-stage AC­TIV-3 tri­al af­ter the drug showed neg­li­gi­ble ef­fect in achiev­ing sus­tained re­cov­ery in hos­pi­tal­ized Covid-19 pa­tients, the part­ners said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.